<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the possibility that myeloid cells from the bone marrow (BM) of myelodysplastic patients differ in their expression of CD44 antigen compared with expression of the antigen in <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, two triple-surface marker assays incorporating, respectively, CD44/CD33/CD66 and CD33/CD34/HLA-DR were used to evaluate the degree of myeloid maturation and assess the number of blasts in BM by flow cytometry </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with early-stage <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; RA [FAB classification]) have significantly decreased expression of CD44 on gated myeloid cells </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, patients with late-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> [FAB classification]) showed an elevated expression of CD44 and an increased number of CD34 blasts compared with early-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="4" pm="."><plain>Late-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients also had an increase in the immature myeloid compartment (CD66 weak expression) compared with early-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="5" pm="."><plain>We have already included this assay as part of our <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> evaluation protocol alongside BM <z:mp ids='MP_0000002'>morphology</z:mp> and cytogenetics </plain></SENT>
</text></document>